Interaction between anti-Alzheimer and antipsychotic drugs in modulating extrapyramidal motor disorders in mice

Journal of Pharmacological Sciences

Volumn 127, Issue 4, 2015, Pages 439-445

  Shimizu, Saki ^a   Mizuguchi, Yuto ^a   Sobue, Akira ^a   Fujiwara, Mai ^a   Morimoto, Tomoki ^a   Ohno, Yukihiro ^a  

^a OSAKA MEDICAL COLLEGE   (Japan)

Author keywords

Anti Alzheimer drugs; Antipsychotic drugs; Behavioral and psychological; Cholinesterase inhibitors; Extrapyramidal side effects; Symptoms of dementia (BPSD)

Indexed keywords

2 DIPROPYLAMINO 8 HYDROXYTETRALIN; DONEPEZIL; GALANTAMINE; HALOPERIDOL; MECAMYLAMINE; ONDANSETRON; RITANSERIN; SB 258585; SEROTONIN 6 ANTAGONIST; TRIHEXYPHENIDYL; UNCLASSIFIED DRUG; CHOLINESTERASE INHIBITOR; INDAN DERIVATIVE; MUSCARINIC RECEPTOR; NEUROLEPTIC AGENT; NOOTROPIC AGENT; PIPERIDINE DERIVATIVE; SEROTONIN 1A RECEPTOR; SEROTONIN RECEPTOR AFFECTING AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ATTENUATION; BRADYKINESIA; CONTROLLED STUDY; CORPUS STRIATUM; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG MEGADOSE; DRUG POTENTIATION; DRUG SAFETY; EXTRAPYRAMIDAL SYMPTOM; LOW DRUG DOSE; MALE; MOUSE; NEUROMODULATION; NONHUMAN; SEROTONINERGIC SYSTEM; SUBSTANTIA NIGRA PARS COMPACTA; ALZHEIMER DISEASE; ANIMAL; CHEMICALLY INDUCED; DRUG INTERACTION; EXTRAPYRAMIDAL SYNDROME; HYPOKINESIA; INBRED MOUSE STRAIN;

ALZHEIMER DISEASE; ANIMALS; ANTIPSYCHOTIC AGENTS; BASAL GANGLIA DISEASES; CHOLINESTERASE INHIBITORS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; GALANTAMINE; HALOPERIDOL; HYPOKINESIA; INDANS; MALE; MICE, INBRED STRAINS; NOOTROPIC AGENTS; PIPERIDINES; RECEPTOR, SEROTONIN, 5-HT1A; RECEPTORS, MUSCARINIC; SEROTONIN AGENTS;

EID: 84936869530     PISSN: 13478613     EISSN: 13478648     Source Type: Journal    
DOI: 10.1016/j.jphs.2015.03.004     Document Type: Article

References (40)

1. Silva T, Reis J, Teixeira J, Borges F. Alzheimer's disease, enzyme targets and drug discovery struggles: from natural products to drug prototypes. Ageing Res Rev. 2014;15:116-145.
2. Lyketsos CG, Sheppard JM, Steinberg M, Tschanz JA, Norton MC, Steffens DC, et al. Neuropsychiatric disturbance in Alzheimer's disease clusters into three groups: the Cache County study. Int J Geriatr Psychiatry. 2001;16:1043-1053.
3. Aalten P, Verhey FR, Boziki M, Bullock R, Byrne EJ, Camus V, et al. Neuropsychiatric syndromes in dementia. Results from the European Alzheimer Disease Consortium: part I. Dement Geriatr Cogn Disord. 2007;24:457-463.
4. Gabryelewicz T. Pharmacological treatment of behavioral symptoms in dementia patients. Przegl Lek. 2014;71:215-220.
5. Fibiger HC. Cholinergic mechanisms in learning, memory and dementia: a review of recent evidence. Trends Neurosci. 1991;14:220-223.
6. Salamone JD, Correa M, Carlson BB, Wisniecki A, Mayorga AJ, Nisenbaum E, et al. Neostriatal muscarinic receptor subtypes involved in the generation of tremulous jaw movements in rodents implications for cholinergic involvement in parkinsonism. Life Sci. 2001;68:2579-2584.
7. Kozman MN, Wattis J, Curran S. Pharmacological management of behavioural and psychological disturbance in dementia. Hum Psychopharmacol. 2006;21:1-12.
8. Schmitt B, Bernhardt T, Moeller HJ, Heuser I, Frölich L. Combination therapy in Alzheimer's disease: a review of current evidence. CNS Drugs. 2004;18:827-844.
9. Horacek J, Bubenikova-Valesova V, Kopecek M, Palenicek T, Dockery C, Mohr P, et al. Mechanism of action of atypical antipsychotic drugs and the neurobiology of schizophrenia. CNS Drugs. 2006;20:389-409.
10. Meltzer HY. The mechanism of action of novel antipsychotic drugs. Schizophr Bull. 1991;17:263-287.
11. Ohno Y, Ishida-Tokuda K, Ishibashi T, Sakamoto H, Tagashira R, Horisawa T, et al. Potential role of 5-HT2 and D2 receptor interaction in the atypical antipsychotic action of the novel succimide derivative, perospirone. Pol J Pharmacol. 1997;49:213-219.
12. Kapur S, Remington G. Atypical antipsychotics: new directions and new challenges in the treatment of schizophrenia. Annu Rev Med. 2001;52:503-517.
13. Meltzer HY, Li Z, Kaneda Y, Ichikawa J. Serotonin receptors: their key role in drugs to treat schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 2003;27:1159-1172.
14. Ohno Y. Therapeutic role of 5-HT1A receptors in the treatment of schizophrenia and Parkinson's disease. CNS Neurosci Ther. 2011;17:58-65.
15. Shimizu S, Mizuguchi Y, Ohno Y. Improving the treatment of schizophrenia: role of 5-HT receptors in modulating cognitive and extrapyramidal motor functions. CNS Neurol Disord Drug Targets. 2013;12:861-869.
16. Shimizu S, Ohno Y. Improving the treatment of Parkinson's disease: a novel approach by modulating 5-HT (1A) receptors. Aging Dis. 2013;4:1-13.
17. Smith Y, Villalba R. Striatal and extrastriatal dopamine in the basal ganglia: an overview of its anatomical organization in normal and Parkinsonian brains. Mov Disord. 2008;23:534-547.
18. Shimizu S, Tatara A, Imaki J, Ohno Y. Role of cortical and striatal 5-HT1A receptors in alleviating antipsychotic-induced extrapyramidal disorders. Prog Neuropsychopharmacol Biol Psychiatry. 2010;34:877-881.
19. Van Dam D, Abramowski D, Staufenbiel M, De Deyn PP. Symptomatic effect of donepezil, rivastigmine, galantamine and memantine on cognitive deficits in the APP23 model. Psychopharmacology (Berl). 2005;180:177-190.
20. Koda K, Ago Y, Kawasaki T, Hashimoto H, Baba A, Matsuda T. Galantamine and donepezil differently affect isolation rearing-induced deficits of prepulse inhibition in mice. Psychopharmacology (Berl). 2008;196:293-301.
21. Ohno Y, Imaki J, Mae Y, Takahashi T, Tatara A. Serotonergic modulation of extrapyramidal motor disorders in mice and rats: role of striatal 5-HT3 and 5-HT6 receptors. Neuropharmacology. 2011;60:201-208.
22. Tatara A, Shimizu S, Shin N, Sato M, Sugiuchi T, Imaki J, et al. Modulation of antipsychotic-induced extrapyramidal side effects by medications for mood disorders. Prog Neuropsychopharmacol Biol Psychiatry. 2012;38:252-259.
23. Ohno Y, Ishida K, Ikeda K, Ishibashi T, Okada K, Nakamura M. Evaluation of bradykinesia induction by SM-9018, a novel 5-HT2 and D2 receptor antagonist, using the mouse pole test. Pharmacol Biochem Behav. 1994;49:19-23.
24. Damsma G, de Boer P, Westerink BH, Fibiger HC. Dopaminergic regulation of striatal cholinergic interneurons: an in vivo microdialysis study. Naunyn Schmiedebergs Arch Pharmacol. 1990;342:523-527.
25. DeBoer P, Abercrombie ED. Physiological release of striatal acetylcholine in vivo: modulation by D1 and D2 dopamine receptor subtypes. J Pharmacol Exp Ther. 1996;277:775-783.
26. Samochocki M, Höffle A, Fehrenbacher A, Jostock R, Ludwig J, Christner C, et al. Galantamine is an allosterically potentiating ligand of neuronal nicotinic but not of muscarinic acetylcholine receptors. J Pharmacol Exp Ther. 2003;305:1024-1036.
27. Ago Y, Koda K, Takuma K, Matsuda T. Pharmacological aspects of the acetylcholinesterase inhibitor galantamine. J Pharmacol Sci. 2011;116:6-17.
28. Takeda M, Tanaka T, Okochi M. New drugs for Alzheimer's disease in Japan. Psychiatry Clin Neurosci. 2011;65:399-404.
29. Giacobini E. Selective inhibitors of butyrylcholinesterase: a valid alternative for therapy of Alzheimer's disease? Drugs Aging. 2001;18:891-898.
30. Ago Y, Koda K, Ota Y, Kita Y, Fukada A, Takuma K, et al. Donepezil, but not galantamine, blocks muscarinic receptor-mediated in vitro and in vivo responses. Synapse. 2011;65:1373-1377.
31. Neumaier JF, Sexton TJ, Yracheta J, Diaz AM, Brownfield M. Localization of 5-HT7 receptors in rat brain by immunocytochemistry, in situ hybridization, and agonist stimulated cFos expression. J Chem Neuroanat. 2001;21:63-73.
32. Hedlund PB, Kelly L, Mazur C, Lovenberg T, Sutcliffe JG, Bonaventure P. 8-OH-DPAT acts on both 5-HT1A and 5-HT7 receptors to induce hypothermia in rodents. Eur J Pharmacol. 2004;487:125-132.
33. Ohno Y, Shimizu S, Imaki J, Ishihara S, Sofue N, Sasa M, et al. Evaluation of the antibradykinetic actions of 5-HT1A agonists using the mouse pole test. Prog Neuropsychopharmacol Biol Psychiatry. 2008;32:1302-1307.
34. Alex KD, Pehek EA. Pharmacologic mechanisms of serotonergic regulation of dopamine neurotransmission. Pharmacol Ther. 2007;113:296-320.
35. Ishibashi T, Ikeda K, Ishida K, Yasui J, Tojima R, Nakamura M, et al. Contrasting effects of SM-9018, a potential atypical antipsychotic, and haloperidol on c-fos mRNA expression in the rat striatum. Eur J Pharmacol. 1996;303:247-251.
36. Ishida K, Ohno Y, Ishibashi T, Nakamura M. Effects of SM-9018, a novel 5-HT2 and D2 receptor antagonist, on electrically-evoked [3H]acetylcholine release from rat striatal slices. Gen Pharmacol. 1996;27:1203-1207.
37. Kapur S, Remington G. Serotonin-dopamine interaction and its relevance to schizophrenia. Am J Psychiatry. 1996;153:466-476.
38. Bonsi P, Cuomo D, Ding J, Sciamanna G, Ulrich S, Tscherter A, et al. Endogenous serotonin excites striatal cholinergic interneurons via the activation of 5-HT2C, 5-HT6, and 5-HT7 serotonin receptors: implications for extrapyramidal side effects of serotonin reuptake inhibitors. Neuropsychopharmacology. 2007;32:1840-1854.
39. Ohno Y, Tatara A, Shimizu S, Sasa M. Management of cognitive impairments in schizophrenia: the therapeutic role of 5-HT receptors. In: Sumiyoshi T, editor. Antipsychotic drugs: pharmacology, side effects and abuse prevention. NY: Nova Science Publishers, Inc.; 2012. p. 323-328.
40. Newman-Tancredi A. The importance of 5-HT1A receptor agonism in antipsychotic drug action: rationale and perspectives. Curr Opin Investig Drugs. 2010;11:802-812.